Drug facts
MoleculeEmtricitabine and Tenofovir Disoproxil (Truvada)
Generics already compete: 9 makers on the market. 21 A-rated products from 9 makers substitute at the counter.
Truvada was first approved by the FDA on 08/02/2004 under NDA 021752; the application holder is Gilead Sciences Inc.
The latest NADAC for EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB is $0.53 per unit (as of 10/28/2026).
Holder Gilead Sciences IncApplication NDA 021752Approved 08/02/2004
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Truvada patent listed in the Orange Book Orange Book
02Competition
- Generics
- 9 generic makers Orange Book
- First generic approved
- 06/08/2017 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Emtricitabine and Tenofovir Disoproxil profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.53 per unitEMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Gilead Sciences Inc Orange Book
- Application
- NDA 021752 Orange Book
- First approved
- 08/02/2004 Orange Book
- Dosage forms
- tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.